Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Leblanc

Showing results (81-90 of 120) with videos related to

Pageof 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2022
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 TrialMeletios A Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, et al.
Cancer Medicine|September 26, 2022
Real-world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group DatabaseHira Mian, Richard LeBlanc, Martha Louzada, et al.
Current Oncology (Toronto, Ont.)|April 25, 2025
Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple MyelomaAndrée-Anne Pelland, Mathilde Dumas, Émilie Lemieux-Blanchard, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 5, 2022
Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group DatabaseHira Mian, Donna Reece, Esther Masih-Khan, et al.
Current Oncology (Toronto, Ont.)|March 24, 2022
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) DatabaseArleigh McCurdy, Christopher P Venner, Esther Masih-Khan, et al.
Journal of Patient Experience|November 6, 2025
Combining Virtual Reality and Hypnosis? A User Experience Study in Patients with Multiple Myeloma Following Stem Cell TransplantationJade Véronneau, Alexandra Chevestrier-Lefeuvre, Valentyn Fournier, et al.
European Journal of Haematology|February 4, 2021
The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myelomaHannah M Cherniawsky, Vishal Kukreti, Donna Reece, et al.
The New England Journal of Medicine|November 8, 2018
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple MyelomaMeletios A Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, et al.
Bone Marrow Transplantation|November 30, 2021
Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II studyRichard LeBlanc, Imran Ahmad, Rafik Terra, et al.
Haematologica|October 15, 2020
The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national databaseHannah M Cherniawsky, Vishal Kukreti, Donna Reece, et al.
Pageof 12

Showing results (81-90 of 120) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2022
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 TrialMeletios A Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, et al.
Cancer Medicine|September 26, 2022
Real-world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group DatabaseHira Mian, Richard LeBlanc, Martha Louzada, et al.
Current Oncology (Toronto, Ont.)|April 25, 2025
Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple MyelomaAndrée-Anne Pelland, Mathilde Dumas, Émilie Lemieux-Blanchard, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 5, 2022
Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group DatabaseHira Mian, Donna Reece, Esther Masih-Khan, et al.
Current Oncology (Toronto, Ont.)|March 24, 2022
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) DatabaseArleigh McCurdy, Christopher P Venner, Esther Masih-Khan, et al.
Journal of Patient Experience|November 6, 2025
Combining Virtual Reality and Hypnosis? A User Experience Study in Patients with Multiple Myeloma Following Stem Cell TransplantationJade Véronneau, Alexandra Chevestrier-Lefeuvre, Valentyn Fournier, et al.
European Journal of Haematology|February 4, 2021
The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myelomaHannah M Cherniawsky, Vishal Kukreti, Donna Reece, et al.
The New England Journal of Medicine|November 8, 2018
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple MyelomaMeletios A Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, et al.
Bone Marrow Transplantation|November 30, 2021
Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II studyRichard LeBlanc, Imran Ahmad, Rafik Terra, et al.
Haematologica|October 15, 2020
The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national databaseHannah M Cherniawsky, Vishal Kukreti, Donna Reece, et al.
Pageof 12